BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Business

  Spectrum Pharmaceuticals Announces Strategic Restructuring

  Spectrum Pharmaceuticals today announced a strategic restructuring.

  January 5, 2022

   · 

  4 min read
• Lone Star Bio

  Genprex to Participate in January 2022 Investor and Healthcare Conferences to Highlight Company’s Gene Therapies in Cancer and Diabetes

  Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced its participation in upcoming investor and healthcare conferences to be held in January 2022.

  January 5, 2022

   · 

  6 min read
• Genetown

  bluebird bio to Present at the 40th Annual J.P. Morgan Healthcare Conference

  bluebird bio to Present at the 40th Annual J.P. Morgan Healthcare Conference.

  January 5, 2022

   · 

  1 min read
• Business

  Mriglobal Chief Science Advisor Part of Ambitious Pandemic Response Team to Speed Drug Cocktails for COVID-19 and future deadly virus waiting in the wings

  MRIGlobal Chief Science Advisor Gene G. Olinger, Ph.D. is a part of an international team of scientists that has have formed a plan for an accelerated pipeline for developing drug cocktails to battle the COVID-19 pandemic.

  January 5, 2022

   · 

  4 min read
• Genetown

  Hologic Adds Aptima SARS-CoV-2 Assay to its Global Access Initiative in Resource-Limited Countries

  Hologic, Inc. announces the addition of the Aptima® SARS-CoV-2 assay to its Global Access Initiative, a program designed to expand access to critical diagnostic testing in resource-limited countries.

  January 5, 2022

   · 

  3 min read
• Business

  VBI Vaccines Announces Dosing of First Patient in Second Phase 2 Study in Chronic Hepatitis B Patients as Part of Expansion of Clinical Collaboration With Brii Bio

  VBI Vaccines Inc. today announced that the first patient has been dosed in a second Phase 2a/2b clinical study evaluating VBI-2601 (BRII-179), an immunotherapeutic candidate targeting chronic hepatitis B virus (HBV).

  January 5, 2022

   · 

  7 min read
• Business

  Inscripta® Appoints Kristala Prather, PhD to its Board of Directors

  Inscripta, Inc., The Digital Genome Engineering Company, today announced that it has appointed Kristala Prather , PhD, to serve on its Board of Directors.

  January 5, 2022

   · 

  4 min read
• Business

  Revelar Biotherapeutics and Twist Bioscience Announce RBT-0813 Neutralizes SARS-CoV-2 Omicron (B.1.1.529/BA.1) and Delta (B.1.617.2) Variants

  Revelar Biotherapeutics, Inc. and Twist Bioscience Corporation (Nasdaq: TWST) today announced that RBT-0813 binds to and neutralizes the Omicron and Delta variants of SARS-CoV-2 in live virus studies.

  January 5, 2022

   · 

  7 min read
• Clover Doses First Participants with Homologous Booster Dose of COVID-19 Vaccine Candidate in SPECTRA

  Clover Biopharmaceuticals, Ltd. today announced that the first participants have been dosed with Clover’s COVID-19 vaccine candidate, SCB-2019,

  January 5, 2022

   · 

  4 min read
• Pharm Country

  Hepion Pharmaceuticals to Present Clinical Data at NASH-TAG Conference

  Hepion Pharmaceuticals, Inc. announced that the Company’s Chief Medical Officer, Dr. Todd Hobbs, will present data from the Phase 2 ‘AMBITION’ study at the NASH-TAG 2022 Conference, which is being held January 6-8, 2022, in Park City, Utah.

  January 5, 2022

   · 

  2 min read